1. Home
  2. XBP vs ACXP Comparison

XBP vs ACXP Comparison

Compare XBP & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XBP

XBP Europe Holdings Inc.

N/A

Current Price

$5.74

Market Cap

96.2M

ML Signal

N/A

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$4.92

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBP
ACXP
Founded
2020
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
96.2M
3.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
XBP
ACXP
Price
$5.74
$4.92
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$143.67
AVG Volume (30 Days)
6.0K
5.8M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$0.29
52 Week High
$8.55
$8.34

Technical Indicators

Market Signals
Indicator
XBP
ACXP
Relative Strength Index (RSI) 36.49 67.56
Support Level $5.06 $3.98
Resistance Level $8.46 $5.28
Average True Range (ATR) 0.49 0.65
MACD -0.14 0.40
Stochastic Oscillator 16.69 72.06

Price Performance

Historical Comparison
XBP
ACXP

About XBP XBP Europe Holdings Inc.

XBP Global Holdings Inc is a multinational technology and services company that drives intelligent workflows for organizations. Through its proprietary platforms, agentic AI-driven automation, and domain expertise across industries and the public and private sectors, the firm enables its clients to entrust their digital transformations and workflows. By combining innovation with execution excellence, XBP Global helps businesses reimagine business process automation and enable digital transformation.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.

Share on Social Networks: